Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 658

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

Chow, Pierce K.H., Gandhi, Mihir, Tan, Say-Beng, Khin, Maung Win, Khasbazar, Ariunaa, Ong, Janus, Choo, Su Pin, Cheow, Peng Chung, Chotipanich, Chanisa, Lim, Kieron, Lesmana, Laurentius A., Manuaba, Tjakra W., Yoong, Boon Koon, Raj, Aloysius, Law, Chiong Soon, Cua, Ian H.Y., Lobo, Rolley R., Teh, Catherine S.C., Kim, Yun Hwan, Jong, Yun Won, Han, Ho-Seong, Bae, Si-Hyun, Yoon, Hyun-Ki, Lee, Rheun-Chuan, Hung, Chien-Fu, Peng, Cheng-Yuan, Liang, Po-Chin, Bartlett, Adam, Kok, Kenneth Y.Y., Thng, Choon-Hua, Low, Albert Su-Chong, Goh, Anthony S.W., Tay, Kiang Hiong, Lo, Richard H.G., Goh, Brian K.P., Ng, David C.E., Lekurwale, Ganesh, Liew, Wei Ming, Gebski, Val, Mak, Kenneth S.W., Soo, Khee Chee, on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group·2018·Journal of Clinical Oncology
DOI 10.1200/jco.2017.76.0892
Open this paper in CoChat — free account

Abstract

Purpose: Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods: SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90 Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population. Results: A total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade ≥ 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade ≥ 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs. Conclusion: In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.0892

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 658

Metadata

Authors
Chow, P. K. H., Gandhi, M., Tan, S.-B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., Lesmana, L. A., Manuaba, T. W., Yoong, B. K., Raj, A., Law, C. S., Cua, I. H. Y., Lobo, R. R., Teh, C. S. C., Kim, Y. H., Jong, Y. W., Han, H.-S., Bae, S.-H., Yoon, H.-K., Lee, R.-C., Hung, C.-F., Peng, C.-Y., Liang, P.-C., Bartlett, A., Kok, K. Y. Y., Thng, C.-H., Low, A. S.-C., Goh, A. S. W., Tay, K. H., Lo, R. H. G., Goh, B. K. P., Ng, D. C. E., Lekurwale, G., Liew, W. M., Gebski, V., Mak, K. S. W., Soo, K. C., & on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2018-07-01
Volume
36
Issue
19
Pages
1913-1921
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2017.76.0892
OpenAlex
W2791703762
Cited by
658
References
27
FWCI
43.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2017.76.0892
The paper
Chow, P. K. H., Gandhi, M., Tan, S.-B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., Lesmana, L. A., Manuaba, T. W., Yoong, B. K., Raj, A., Law, C. S., Cua, I. H. Y., Lobo, R. R., Teh, C. S. C., Kim, Y. H., . . . on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group. (2018). SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.0892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.